NCT03830619 is a clinical trial of collect samples in Lung Cancer (Diagnosis), sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT03830619?

Interventions in NCT03830619: collect samples.

What condition does NCT03830619 study?

NCT03830619 studies Lung Cancer (Diagnosis).

Is NCT03830619 still recruiting?

NCT03830619 is currently completed. Last updated 22 November 2021.

Last reviewed 2021-11-22 · How we verify

NCT03830619

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Serum Exosomal Long Noncoding RNAs as Potential Biomarkers for Lung Cancer Diagnosis

Completed Last updated 22 November 2021

What this trial tests

trial testing collect samples in Lung Cancer (Diagnosis) in 1,000 participants. Completed in 31 July 2021.

Timeline

1 January 2017

Primary endpoint
31 December 2020

31 July 2021

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	1 January 2017
Primary completion	31 December 2020
Estimated completion	31 July 2021
Sites	1 location across China

Drugs / interventions tested

collect samples

Conditions studied

Lung Cancer (Diagnosis) — all drugs for Lung Cancer (Diagnosis) →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

Adults 18 to 75, any sex, with Lung Cancer (Diagnosis). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is to investigate the sensitivity and specificity of serum exosome noncoding RNA as a biomarker for the diagnosis of lung cancer

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Noncoding RNA therapeutics - challenges and potential solutions.
Winkle M, El-Daly SM, Fabbri M, Calin GA. · · 2021 · cited 1123× · PMID 34145432 · DOI 10.1038/s41573-021-00219-z
Exosome-based immunotherapy: a promising approach for cancer treatment.
Xu Z, Zeng S, Gong Z, Yan Y. · · 2020 · cited 373× · PMID 33183286 · DOI 10.1186/s12943-020-01278-3
Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm.
Yin K, Wang S, Zhao RC. · · 2019 · cited 290× · PMID 30992990 · DOI 10.1186/s40364-019-0159-x
Progress on pivotal role and application of exosome in lung cancer carcinogenesis, diagnosis, therapy and prognosis.
Li MY, Liu LZ, Dong M. · · 2021 · cited 185× · PMID 33504342 · DOI 10.1186/s12943-021-01312-y
Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications.
Huda MN, Nafiujjaman M, Deaguero IG, Okonkwo J, et al · · 2021 · cited 160× · PMID 33988964 · DOI 10.1021/acsbiomaterials.1c00217
The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy.
Jiang W, Pan S, Chen X, Wang ZW, et al · · 2021 · cited 124× · PMID 34496886 · DOI 10.1186/s12943-021-01406-7
Mechanisms of Long Non-Coding RNAs in Cancers and Their Dynamic Regulations.
Zhang XZ, Liu H, Chen SR. · · 2020 · cited 109× · PMID 32429086 · DOI 10.3390/cancers12051245
Synergies in exosomes and autophagy pathways for cellular homeostasis and metastasis of tumor cells.
Salimi L, Akbari A, Jabbari N, Mojarad B, et al · · 2020 · cited 102× · PMID 32426106 · DOI 10.1186/s13578-020-00426-y

Verify or expand the search:

Other recruiting trials for Lung Cancer (Diagnosis)

Currently open trials in the same condition.

NCT07168993 — Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Di · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07510724 — Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07241182 — Antrodia Cinnamomea Extract Effects on Lung Cancer Patients' Quality of Life During Chemotherapy · NA · recruiting

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03830619 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 22 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03830619.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing